secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kairos Pharma, LTD. (KAPA)
CIK:        0001962011
Form:       8-K
Filed at:   2025-10-07T23:59:59+00:00
Accession:  0001493152-25-017208
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Kairos Pharma to Present Phase 2 Prostate Cancer Data at ESMO 2025
------------------------------------------------------------------

- On October 7, 2025, Kairos issued press release announcing ESMO Congress presentation in Berlin from October 17-21.
- Presentation covers interim analysis of Phase 2 trial evaluating ENV105 (carotuximab) plus apalutamide in mCRPC.
- Trial enrolling 100 men at Cedars-Sinai, City of Hope, and Huntsman Cancer Institute.
- On October 1, 2025, Kairos Board approved novation agreements with Cedars-Sinai and Tracon to transfer patent licenses from Enviro to Kairos.
- Transferred patents include exclusive licenses for mitochondrial DNA depletion and endoglin antagonism therapies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1962011/000149315225017208/0001493152-25-017208-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1962011/000149315225017208/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-017208

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer